{
    "name": "benzoyl peroxide/clindamycin topical",
    "comment": "Rx",
    "other_names": [
        "BenzaClin",
        "Acanya",
        "Duac",
        "Onexton"
    ],
    "classes": [
        "Acne Agents",
        "Topical Combos"
    ],
    "source": "https://reference.medscape.com/drug/benzaclin-acanya-clindamycin-topical-benzoyl-peroxide-343468",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant women to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; limited published data on use of clindamycin in pregnant women with exposure during first trimester are insufficient to inform a drug-associated risk of pregnancy-related adverse outcomes; in limited published clinical trials with pregnant women, systemic administration of clindamycin during second and third trimesters has not been associated with an increased frequency of major birth defects"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, clindamycin did not cause malformations or embryo-fetal development toxicity in pregnant rats and mice when administered during the period of organogenesis at systemic doses up to 240 times maximum recommended human dose (MRHD) of 2.5 g, based on body surface area (BSA) comparisons"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of clindamycin or benzoyl peroxide in human milk, effects on breastfed child, or on milk production following topical administration; however, clindamycin has been reported to be present in breast milk in small amounts following oral and parenteral administration",
            "Developmental and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to clindamycin, benozyl peroxide, lincomycin or any of the drug components",
                "History of regional enteritis, ulcerative colitis or antibiotic-associated colitis (including pseudomembranous colitis)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Should be used with caution in atopic individuals",
                "For external use only; avoid contact with eyes and mucous membranes",
                "Minimize sun expsoure following application",
                "May have bleaching effects on hair or colored fabric",
                "Bacterial of fungal superinfection may result from prolonged use",
                "Concomitant topical acne therapy may result in cumulative irritancy, especially with use of peeling, desquamating, or abrasive agents; if irritancy or dermatitis occurs, reduce frequency of application or temporarily interrupt treatment and resume once irritation subsides; discontinue treatment if irritation persists",
                "Do not use clindamycin and erythromycin containing products together"
            ],
            "specific": [
                {
                    "type": "Colitis",
                    "description": [
                        "Systemic absorption of clindamycin has been demonstrated following topical use; diarrhea, and colitis (including pseudomembranous colitis) reported with topical use; discontinue immediately if significant diarrhea occurs and consider large bowel endoscopy",
                        "Severe colitis reported following oral and parenteral administration of clindamycin with onset occurring up to several weeks following cessation of therapy; antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis; severe colitis may result in death",
                        "Clostridia is one primary cause of antibiotic-associated colitis; colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus; stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dapsone topical",
            "description": {
                "common": "benzoyl peroxide, dapsone topical. unspecified interaction mechanism. Use Caution/Monitor. Coadministration may cause temporary local yellow or orange discoloration of the skin and facial hair."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Application site pain",
            "percent": null
        },
        {
            "name": "Application site exfoliation",
            "percent": null
        },
        {
            "name": "Application site irritation",
            "percent": null
        },
        {
            "name": "Erythema",
            "percent": null
        },
        {
            "name": "Burning",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Sunburn",
            "percent": null
        },
        {
            "name": "Scaling",
            "percent": null
        },
        {
            "name": "Dryness",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Colitis",
            "percent": null
        },
        {
            "name": "Peeling",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        },
        {
            "name": "as well as allergic reactions leading to hospitalization",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "application site reactions",
            "percent": null
        },
        {
            "name": "including discoloration",
            "percent": null
        }
    ]
}